Combination Therapy in Experimental and Clinical Candidosis
Antimycotic chemotherapy for deep-seated candidosis in patients with reduced immune-defense is still a problem. Only a few antimycotics are available for systemic use and all have their limitations. Thus, interest in drug combinations is increasing in the hope of improving the efficacy and the spectrum of antimycotic therapy.
KeywordsCandida Infection Triple Combination Heroin Addict Ergosterol Biosynthesis Triazole Derivative
Unable to display preview. Download preview PDF.
- 4.A. Polak, 5- Fluorocytosine et associations, Ann.Biol.Clin., 45: 669 (1987).Google Scholar
- 7.J.E. Bennett, W.E. Dismukes, R.J. Duma, G. Medoff, M.A. Sande et al., A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis, New Engl. J.Med., 301: 127 (1979).Google Scholar
- 8.A. Polak, Combined therapy of systematic mycoses, in: Proc. 13th Intern. Congr. Chemother., Vienna 1983, K.H.Spitzy and K.Karrer, eds., Symposia 49/1 and 49/2, part 20, pp. 2–9, H.Egermann, Vienna (1983).Google Scholar
- 9.J.E. Bennett, R.M. Kliegman, A.A. Fanaroff, Disseminated fungal infections in very lowbirth-weight infants: therapeutic toxicity, Pediatrics, 73: 153 (1984).Google Scholar
- 11.D. Armstrogn, Problems in the management of opportunistic fungal infections, 9th Ian Murray Memorial Lecture, Brit.Soc.Mycopathol. (1986).Google Scholar
- 15.M.A. Viviani and A.M. Tortorano, Management of cryptococcosis in AIDS patients, Xth Congr. ISHAM, Barcelona 1988, poster N.RT17–1.Google Scholar
- 16.D. Borelli, A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis, Rev.Infect.Dis., 9 (Suppl. 1) 557 (1987).Google Scholar